Aethlon Medical raises $3.3 million through private placement

Aethlon Medical Inc. (NASDAQ: AEMD) announced it has entered into a securities purchase agreement with an institutional investor for a private placement expected to generate approximately $3.3 million in gross proceeds before fees and expenses.

The San Diego-based medical device company will sell 595,897 shares of common stock or pre-funded warrants, along with warrants to purchase up to 1,042,820 additional shares. The combined offering price per share and accompanying warrant is $4.03, with warrants exercisable at $4.03 per share upon shareholder approval and expiring five and one-half years after approval.

The transaction includes a warrant inducement agreement where the investor will exercise existing warrants issued in March 2025 and September 2025 at a reduced exercise price of $4.03. The investor agreed to exercise March 2025 warrants for 155,000 shares and September 2025 warrants for 55,555 shares. In exchange for immediate exercise, Aethlon will issue new warrants to purchase 368,471 shares at $4.03 per share with the same exercise terms.

Maxim Group LLC serves as the sole placement agent for the offering, which is expected to close on or about December 8, 2025, subject to customary closing conditions.

The securities are being sold through a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered. The company has agreed to file a registration statement with the Securities and Exchange Commission for resale of the securities.

Aethlon Medical develops the Hemopurifier, a medical device designed to remove pathogenic targets from biological fluids for treating cancer and infectious diseases.

You May Also Be Interested In

• Elong Power closes $6.6M public offering on Nasdaq
• Banzai prices $0.9M public offering at $2.75 per share
• Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®